Chemotherapy for Gastric Cancer Patients - Time for Personalization in Medicine?

Overview

Journal Contemp Oncol (Pozn)

Publisher Termedia

Specialty Oncology

Date 2013 Jun 22

PMID 23788860

Citations 2

Authors

Elzbieta Nowara

Agnieszka Boratyn-Nowicka

Anna Polakiewicz-Gilowska

Anna Drosik

Magdalena Kustra

Joanna Huszno

Affiliations

Soon will be listed here.

Abstract

Gastric cancer is one of the most frequent neoplasms. Although the incidence of gastric cancer worldwide has declined, there is still high mortality. Treatment of inoperable disease is under evaluation in clinical trials. In palliative treatment chemotherapy containing cisplatin and 5-fluorouracil is the most widely used. In the past years progress in tumour biology has advanced greatly and has led to development of new molecules aimed at targets important for cancer expansion. There are several randomized trials under targeted therapies for gastric cancer patients. One of them led to approval of trastuzumab. In the current paper the authors illustrate new possibilities in systemic treatment with particular attention to targeted therapy and personalization in medicine.

Citing Articles

Isolated ovarian metastasis of gastric cancer: Krukenberg tumor.

Uyeturk U, Arslan S, Bal O, Yalcintas Arslan U, Cakmak Oksuzoglu O Contemp Oncol (Pozn). 2014; 17(6):515-9.

PMID: 24592139 PMC: 3934036. DOI: 10.5114/wo.2013.37542.

Role of Notch signaling pathway in gastric cancer pathogenesis.

Brzozowa M, Mielanczyk L, Michalski M, Malinowski L, Kowalczyk-Ziomek G, Helewski K Contemp Oncol (Pozn). 2013; 17(1):1-5.

PMID: 23788953 PMC: 3685346. DOI: 10.5114/wo.2013.33765.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Sun Q, Hang M, Xu W, Mao W, Hang X, Li M . Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer. Jpn J Clin Oncol. 2009; 39(12):791-6. DOI: 10.1093/jjco/hyp116. View

Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden P, Haglund U . Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997; 8(2):163-8. DOI: 10.1023/a:1008243606668. View

Javle M, Hsueh C . Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol. 2010; 3:11. PMC: 2856525. DOI: 10.1186/1756-8722-3-11. View

Wagner A, Grothe W, Haerting J, Kleber G, Grothey A, Fleig W . Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24(18):2903-9. DOI: 10.1200/JCO.2005.05.0245. View

Vanhoefer U, Rougier P, Wilke H, Ducreux M, Lacave A, Van Cutsem E . Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the.... J Clin Oncol. 2000; 18(14):2648-57. DOI: 10.1200/JCO.2000.18.14.2648. View

Shah M, Jhawer M, Ilson D, Lefkowitz R, Robinson E, Capanu M . Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2010; 29(7):868-74. PMC: 3646322. DOI: 10.1200/JCO.2010.32.0770. View

Okines A, Verheij M, Allum W, Cunningham D, Cervantes A . Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v50-4. DOI: 10.1093/annonc/mdq164. View

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F . Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358(1):36-46. DOI: 10.1056/NEJMoa073149. View

10.

Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A . Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009; 10(11):1063-9. DOI: 10.1016/S1470-2045(09)70259-1. View

11.

Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M . Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995; 71(3):587-91. PMC: 2033628. DOI: 10.1038/bjc.1995.114. View

12.

Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C . Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008; 19(8):1450-1457. DOI: 10.1093/annonc/mdn166. View

13.

Park D, Yun J, Park J, Oh S, Kim H, Cho Y . HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006; 51(8):1371-9. DOI: 10.1007/s10620-005-9057-1. View

14.

Kitagawa Y, Ueda M, Ando N, Ozawa S, Shimizu N, Kitajima M . Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res. 1996; 2(5):909-14. View

15.

Kim N, Park Y, Heo D, Suh C, Kim S, Park K . A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993; 71(12):3813-8. DOI: 10.1002/1097-0142(19930615)71:12<3813::aid-cncr2820711205>3.0.co;2-5. View

16.

Shah M, Ramanathan R, Ilson D, Levnor A, DAdamo D, OReilly E . Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006; 24(33):5201-6. DOI: 10.1200/JCO.2006.08.0887. View

17.

Van Cutsem E, Moiseyenko V, Tjulandin S, Majlis A, Constenla M, Boni C . Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24(31):4991-7. DOI: 10.1200/JCO.2006.06.8429. View

18.

Webb A, Cunningham D, Scarffe J, Harper P, Norman A, Joffe J . Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997; 15(1):261-7. DOI: 10.1200/JCO.1997.15.1.261. View

19.

COCCONI G, Carlini P, Gamboni A, Gasperoni S, Rodino C, Zironi S . Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol. 2003; 14(8):1258-63. DOI: 10.1093/annonc/mdg329. View

20.

Murad A, Santiago F, Petroianu A, Rocha P, Rodrigues M, Rausch M . Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993; 72(1):37-41. DOI: 10.1002/1097-0142(19930701)72:1<37::aid-cncr2820720109>3.0.co;2-p. View